Prognostic Significance of Oligoclonal Bands and Their Subtypes in Relapsing-Remitting Multiple Sclerosis

dc.contributor.author Ozakbas, Serkan
dc.contributor.author Alizada, Said
dc.contributor.author Cevik, Sumeyye
dc.contributor.author Samadzade, Ulvi
dc.contributor.author Yapici, Nurbanu Aygunduz
dc.contributor.author Zengin, Ela Simay
dc.contributor.author Caliskan, Can
dc.date.accessioned 2025-11-25T15:25:22Z
dc.date.available 2025-11-25T15:25:22Z
dc.date.issued 2025
dc.description.abstract Objective: To investigate the long-term prognostic significance of cerebrospinal fluid oligoclonal band (OCB) positivity and its subtypes (Type 2 and Type 3) in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: This retrospective cohort included 2324 RRMS patients diagnosed using the 2017 McDonald criteria. All patients had documented OCB status and at least 2 years of clinical follow-up; a subset had 5-year data. Outcomes included Expanded Disability Status Scale (EDSS), annualised relapse rate (ARR), and conversion to secondary progressive MS (SPMS). Subgroup analysis compared Type 2 and Type 3 OCBpositive patients. Results: OCB positivity was observed in 82.4 % of patients. At year 2, no significant differences in EDSS, ARR, or SPMS conversion were found between OCB-positive and OCB-negative groups. However, by year 5, the OCBpositive group had a significantly higher rate of conversion to SPMS (p < 0.05). Subgroup analysis showed that Type 3 OCB patients had significantly lower EDSS scores at year 2 compared to Type 2 (p < 0.05), but this difference disappeared at year 5. Conclusion: OCB positivity may be associated with a higher risk of progression to SPMS over the long term. Type 3 OCB may indicate a milder early disease course, although its protective effect diminishes over time. Incorporating OCB subtype analysis into RRMS prognosis may enhance early risk stratification. en_US
dc.identifier.doi 10.1016/j.msard.2025.106813
dc.identifier.issn 2211-0348
dc.identifier.issn 2211-0356
dc.identifier.scopus 2-s2.0-105019946738
dc.identifier.uri https://doi.org/10.1016/j.msard.2025.106813
dc.identifier.uri https://hdl.handle.net/20.500.14365/6614
dc.language.iso en en_US
dc.publisher Elsevier Sci Ltd en_US
dc.relation.ispartof Multiple Sclerosis and Related Disorders en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Relapsing-Remitting Multiple Sclerosis en_US
dc.subject Oligoclonal Bands en_US
dc.subject Cerebrospinal Fluid en_US
dc.subject Prognostic Biomarkers en_US
dc.subject Secondary Progressive MS en_US
dc.title Prognostic Significance of Oligoclonal Bands and Their Subtypes in Relapsing-Remitting Multiple Sclerosis en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.scopusid 6602895100
gdc.author.scopusid 60105907600
gdc.author.scopusid 57407496500
gdc.author.scopusid 58643660800
gdc.author.scopusid 60105907700
gdc.author.scopusid 59603512800
gdc.author.scopusid 59603512800
gdc.author.wosid Caliskan, Can/Gwv-1401-2022
gdc.author.wosid Ozakbas, Serkan/V-6427-2019
gdc.author.wosid Alizada, Said/Jfs-7648-2023
gdc.author.wosid Zengin, Ela/Omk-7035-2025
gdc.bip.impulseclass C5
gdc.bip.influenceclass C5
gdc.bip.popularityclass C5
gdc.coar.access metadata only access
gdc.coar.type text::journal::journal article
gdc.collaboration.industrial false
gdc.description.department İzmir Ekonomi Üniversitesi en_US
gdc.description.departmenttemp [Ozakbas, Serkan; Samadzade, Ulvi; Caliskan, Can] Izmir Univ Econ, Neurol Clin, Sakarya St 156 Balcova, TR-35330 Balcova, Izmir, Turkiye; [Alizada, Said] Dokuz Eylul Univ, Dept Neurol, Mithatpasa Cad 1606,9 Eylul Hosp, TR-35210 Alsancak, Izmir, Turkiye; [Cevik, Sumeyye] Dokuz Eylul Univ, Inst Hlth Sci, Dept Neurosci, TR-35340 Balcova, Izmir, Turkiye; [Yapici, Nurbanu Aygunduz] Dokuz Eylul Univ, Dept Neurol, Mithatpasa Cad 1606,9 Eylul Hosp, TR-35210 Alsancak, Izmir, Turkiye; [Zengin, Ela Simay] Izmir Univ Econ, Dept Neurol, TR-35330 Izmir, Turkiye en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q2
gdc.description.startpage 106813
gdc.description.volume 104 en_US
gdc.description.woscitationindex Science Citation Index Expanded
gdc.description.wosquality Q2
gdc.identifier.openalex W4415534078
gdc.identifier.pmid 41161151
gdc.identifier.wos WOS:001609065800001
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type PubMed
gdc.oaire.diamondjournal false
gdc.oaire.impulse 0.0
gdc.oaire.influence 2.4895952E-9
gdc.oaire.isgreen false
gdc.oaire.popularity 2.7494755E-9
gdc.oaire.publicfunded false
gdc.openalex.collaboration National
gdc.openalex.fwci 0.0
gdc.openalex.normalizedpercentile 0.56
gdc.opencitations.count 0
gdc.plumx.mendeley 1
gdc.plumx.newscount 1
gdc.plumx.scopuscites 0
gdc.scopus.citedcount 0
gdc.virtual.author Özakbaş, Serkan
gdc.wos.citedcount 0
relation.isAuthorOfPublication 0750ade3-1d29-450d-8c26-aaa8708d1bb0
relation.isAuthorOfPublication.latestForDiscovery 0750ade3-1d29-450d-8c26-aaa8708d1bb0
relation.isOrgUnitOfPublication 7b4bd652-27ef-4beb-a10e-dddd2d65e0fd
relation.isOrgUnitOfPublication fbc53f3e-d1d3-4168-afd8-e42cd20bddd9
relation.isOrgUnitOfPublication e9e77e3e-bc94-40a7-9b24-b807b2cd0319
relation.isOrgUnitOfPublication.latestForDiscovery 7b4bd652-27ef-4beb-a10e-dddd2d65e0fd

Files